Get the Stockscreener App
11.84
0.75%
-0.09
Omeros Corp stock is traded at $11.84, with a volume of 1.30M.
It is down -0.75% in the last 24 hours and up +24.50% over the past month.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
See More
Previous Close:
$11.93
Open:
$11.93
24h Volume:
1.30M
Relative Volume:
0.73
Market Cap:
$856.92M
Revenue:
-
Net Income/Loss:
$84.01M
P/E Ratio:
13.83
EPS:
0.856
Net Cash Flow:
$-101.16M
1W Performance:
+20.94%
1M Performance:
+24.50%
6M Performance:
+1.28%
1Y Performance:
+205.94%
1-Day Range:
$11.37
$11.99
1-Week Range:
$10.50
$12.16
52-Week Range:
$3.435
$17.65
Omeros Corp Stock (OMER) Company Profile
Name
Omeros Corp
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corp
|
11.84 | 820.74M | 0 | 84.01M | -101.16M | 0.856 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Omeros Corp Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Initiated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corp Stock (OMER) Latest News
H.C. Wainwright reiterates Omeros stock rating on rival trial miss By Investing.com - Investing.com Canada
Omeros Corp (OMER) Valuation: PE, PB & Fair Value Analysis - TradingKey
Omeros Corp (OMER) Institutional Confidence - TradingKey
Omeros Corp (OMER) Stock Jumps 12% After AstraZeneca Setback, Valuation Reflects Growth Uncertainty - GuruFocus
AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst – A Look At Some Key Highlights - Stocktwits
OMER | Omeros Corporation FinancialsIncome Statement - Quiver Quantitative
Omeros Corp (OMER) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Omeros Corp (OMER) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Form 4 Omeros Corporation For: 24 July By Investing.com - Investing.com South Africa
OMER|Omeros Corp|Price:11.340|Chg%:+1.550 - TradingKey
Omeros Corp (OMER) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Omeros Corp (OMER) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OMER Stock Surges 5% After Hours On Novo Nordisk Deal Windfall And Drug Launch Optimism - Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - GlobeNewswire Inc.
OMER6080787 Bond Profile — Key Metrics - TradingView
Omeros repurchases $14.5M of 9.50% convertible notes, total retirements $30.5M - TradingView
OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment - Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros CorporationOMER - PR Newswire
EMA Committee Rejects Marketing Authorization for Omeros Corp Antibody Narsoplimab - sekbernews.id
Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return - Yahoo Finance
Omeros Corporation Investigated by the Portnoy Law Firm - GlobeNewswire Inc.
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026? - AOL.com
Omeros shares drop 19% after EMA rejects narsop... - Pluang
Omeros: Yartemlea Faces Headwinds While We Wait On Pipeline Developments - Seeking Alpha
Is Omeros Corporation (OMER) the Best Get Rich Quick Stock to Buy Right Now? - Insider Monkey
Omeros Corporation Files SEC Form 8-K for Other Events – Nasdaq: OMER, July 2026 - Minichart
Omeros to repurchase $16M of 9.50% notes, may buy up to $14.5M more - TradingView
Omeros (NASDAQ: OMER) expands 2029 note repurchases and weighs new debt - Stock Titan
Omeros Corporation Reports First Quarter 2026 Financial Results - The National Law Review
Omeros stock drops 19% after EU rejects key dru... - Pluang
OMEROS CORP (OMER) Stock Chart - ChartMill
Omeros stock crashes on regulatory setback: Buy the dip? - MSN
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session - Benzinga
FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide - Sahm
Crude Oil Falls 4%; US Consumer Sentiment Rises In June - Sahm
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026? - AOL.com
Omeros Corp (OMER) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Omeros (OMER) Faces Regulatory Setback for Narsoplimab Approval - GuruFocus
Omeros stock crashes on regulatory setback: buy the dip? - Invezz
Omeros Corp Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
Omeros Corp Stock (OMER) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cable Thomas J. | Director |
May 22 '26 |
Sale |
11.61 |
7,500 |
87,039 |
35,067 |
2.44%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):